cn-biopharma-patent-drafting

Warn

Audited by Snyk on Aug 27, 2026

Risk Level: MEDIUM
Full Analysis

MEDIUM W011: Third-party content exposure detected (indirect prompt injection risk).

  • Third-party content exposure detected (medium risk: 0.30). 工作流程步骤3在进行“新颖性评估”时会把用户输入的tech_solution提交给novelty_lite_submit/patsnap_search进行专利检索与结果获取,从而让LLM在运行时摄取由第三方来源(专利文本/摘要/描述/权利要求等)产生的内容。

Issues (1)

W011
MEDIUM

Third-party content exposure detected (indirect prompt injection risk).

Audit Metadata
Risk Level
MEDIUM
Analyzed
Aug 27, 2026, 01:23 AM
Issues
1